Source: FDA, National Drug Code (US) Revision Year: 2020
EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.
It is recommended that a healthcare provider discuss with the patient or caregiver how to prepare the prescribed daily dose prior to administration of the first dose [see Instructions for Use].
Instruct patients or caregivers to prepare the dose using the reusable oral syringe provided.
EVRYSDI must be taken immediately after it is drawn up into the oral syringe. If EVRYSDI is not taken within 5 minutes, EVRYSDI should be discarded from the oral syringe, and a new dose should be prepared.
EVRYSDI is taken orally once daily after a meal at approximately the same time each day.
In infants who are breastfed, EVRYSDI should be administered after breastfeeding. EVRYSDI cannot be mixed with formula or milk.
Instruct patients to drink water after taking EVRYSDI to ensure the drug has been completely swallowed.
If the patient is unable to swallow and has a nasogastric or gastrostomy tube, EVRYSDI can be administered via the tube. The tube should be flushed with water after delivering EVRYSDI [see Instructions for Use].
EVRYSDI is administered orally once daily. The recommended dosage is determined by age and body weight (see Table 1).
Table 1. Adult and Pediatric Dosing Regimen by Age and Body Weight:
Age and Body Weight | Recommended Daily Dosage |
---|---|
2 months to less than 2 years of age | 0.2 mg/kg |
2 years of age and older weighing less than 20 kg | 0.25 mg/kg |
2 years of age and older weighing 20 kg or more | 5 mg |
If a dose of EVRYSDI is missed, EVRYSDI should be administered as soon as possible if still within 6 hours of the missed dose, and the usual dosing schedule can be resumed on the next day. Otherwise, the missed dose should be skipped, and the next dose should be taken at the regularly scheduled time on the next day.
If a dose is not fully swallowed or vomiting occurs after taking a dose of EVRYSDI, another dose should not be administered to make up for the lost dose. The patient should wait until the next day to take the next dose at the regularly scheduled time.
EVRYSDI powder must be constituted to the oral solution by a pharmacist prior to dispensing to the patient.
The EVRYSDI “Instructions for Constitution” booklet contains more detailed instructions on the preparation of the oral solution [see Instructions for Constitution].
Caution should be exercised in the handling of EVRYSDI powder for oral solution. Avoid inhalation and direct contact with skin or mucous membranes with the dry powder and the constituted solution. If such contact occurs, wash thoroughly with soap and water; rinse eyes with water. Wear disposable gloves during the preparation and cleanup procedure.
Keep the constituted oral solution of EVRYSDI in the original amber bottle to protect from light. Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Discard any unused portion 64 days after constitution. Keep the bottle in an upright position with the cap tightly closed.
Store the dry powder at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP controlled room temperature]. Keep in the original carton.
Keep the constituted oral solution of EVRYSDI in the original amber bottle to protect from light. Store in a refrigerator at 2°C to 8°C (36°F to 46°F) [see Dosage and Administration (2.4)].
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.